GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Beneish M-Score

DMK Pharmaceuticals (DMK Pharmaceuticals) Beneish M-Score : 6.07 (As of May. 06, 2024)


View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 6.07 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for DMK Pharmaceuticals's Beneish M-Score or its related term are showing as below:

DMKPQ' s Beneish M-Score Range Over the Past 10 Years
Min: -9.89   Med: -2.43   Max: 94.43
Current: 6.07

During the past 13 years, the highest Beneish M-Score of DMK Pharmaceuticals was 94.43. The lowest was -9.89. And the median was -2.43.


DMK Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for DMK Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Beneish M-Score Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.52 -2.70 -9.89 94.43 0.60

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.89 0.60 0.25 4.32 6.07

Competitive Comparison of DMK Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMK Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Beneish M-Score falls into.



DMK Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of DMK Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0+0.528 * 6.8287+0.404 * 28.2759+0.892 * 2.3476+0.115 * 0.4248
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4748+4.679 * -1.178743-0.327 * 2.0411
=6.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0.009 + 0.007 + 1.453 + 2.151 = $3.62 Mil.
Gross Profit was -0.329 + -0.354 + -0.335 + -0.331 = $-1.35 Mil.
Total Current Assets was $7.87 Mil.
Total Assets was $8.96 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.64 Mil.
Selling, General, & Admin. Expense(SGA) was $14.48 Mil.
Total Current Liabilities was $13.46 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -1.388 + -8.574 + -8.943 + -3.328 = $-22.23 Mil.
Non Operating Income was 1.544 + -2.193 + -2.587 + 0.937 = $-2.30 Mil.
Cash Flow from Operations was -3.737 + -2.569 + -1.548 + -1.522 = $-9.38 Mil.
Total Receivables was $1.55 Mil.
Revenue was 1.506 + 0.04 + 1.155 + -1.159 = $1.54 Mil.
Gross Profit was -0.142 + -0.649 + -0.309 + -2.824 = $-3.92 Mil.
Total Current Assets was $10.09 Mil.
Total Assets was $12.14 Mil.
Property, Plant and Equipment(Net PPE) was $2.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.48 Mil.
Selling, General, & Admin. Expense(SGA) was $12.99 Mil.
Total Current Liabilities was $8.87 Mil.
Long-Term Debt & Capital Lease Obligation was $0.06 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 3.62) / (1.554 / 1.542)
=0 / 1.007782
=0

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-3.924 / 1.542) / (-1.349 / 3.62)
=-2.544747 / -0.372652
=6.8287

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (7.872 + 0) / 8.957) / (1 - (10.088 + 1.997) / 12.137)
=0.121134 / 0.004284
=28.2759

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3.62 / 1.542
=2.3476

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.475 / (1.475 + 1.997)) / (0.635 / (0.635 + 0))
=0.424827 / 1
=0.4248

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14.483 / 3.62) / (12.994 / 1.542)
=4.000829 / 8.426719
=0.4748

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 13.462) / 8.957) / ((0.063 + 8.874) / 12.137)
=1.502959 / 0.736343
=2.0411

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-22.233 - -2.299 - -9.376) / 8.957
=-1.178743

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

DMK Pharmaceuticals has a M-score of 6.07 signals that the company is likely to be a manipulator.


DMK Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Executives
Dorbin John W. Jr. officer: General Counsel C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen officer: CFO C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi director, officer: CEO 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi director 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio director 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd director, 10 percent owner, officer: President/CEO PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss officer: Chief Medical Officer 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto officer: Chief Financial Officer 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai director 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins officer: Chief Financial Officer 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels officer: Vice President of Operations 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf director C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams director 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134